KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics has reported Capital Leases over the past 3 years, most recently at $122000.0 for Q3 2025.

  • Quarterly results put Capital Leases at $122000.0 for Q3 2025, down 20.26% from a year ago — trailing twelve months through Sep 2025 was $122000.0 (down 20.26% YoY), and the annual figure for FY2024 was $146000.0, down 15.61%.
  • Capital Leases for Q3 2025 was $122000.0 at Aquestive Therapeutics, down from $130000.0 in the prior quarter.
  • Over the last five years, Capital Leases for AQST hit a ceiling of $173000.0 in Q4 2023 and a floor of $122000.0 in Q3 2025.
  • Median Capital Leases over the past 3 years was $149500.0 (2024), compared with a mean of $148625.0.
  • Biggest five-year swings in Capital Leases: fell 15.61% in 2024 and later fell 20.26% in 2025.
  • Aquestive Therapeutics' Capital Leases stood at $173000.0 in 2023, then dropped by 15.61% to $146000.0 in 2024, then decreased by 16.44% to $122000.0 in 2025.
  • The last three reported values for Capital Leases were $122000.0 (Q3 2025), $130000.0 (Q2 2025), and $138000.0 (Q1 2025) per Business Quant data.